Developer docs
API playgroundTry for free, no card

Search company profiles

Cognixion

Full company profile

uuid0000dtm

Namestring
Cognixion
Legal namestring
COGNIXION, INC.
Websiteurl
cognixion.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Cognixion is a Santa Barbara-headquartered neurotechnology company founded in 2014 by Andreas Forsland that develops non-invasive brain-computer interface (BCI) products to restore communication and environmental control for individuals with severe motor and speech impairments, including ALS, spinal cord injury, stroke, cerebral palsy, and locked-in syndrome. Its core platform combines EEG-based neural signal acquisition, augmented reality (AR) display, eye tracking, head-pose sensing, and adaptive AI language models into a wearable headset (Cognixion ONE / Axon-R) that lets users generate text and speech through thought, gaze, or facial expressions. The company also sells Speakprose and Speakprose Pro+, consumer AAC apps on the Apple App Store that leverage the Apple TrueDepth camera for eye and facial tracking, and a Nucleus bio-sensing hub that integrates with Apple Vision Pro's accessibility APIs in an ongoing clinical study.

The business model combines consumer software subscriptions (Speakprose at $9.99/month, $99.99/year, or $149.99 one-time), research-hardware sales of the Axon-R platform through direct sales and a distribution partnership with Blackrock Neurotech, and a future medical-device revenue stream gated on FDA clearance of Cognixion ONE, after which CMS accreditation as a durable medical equipment supplier is expected to enable Medicare, Medicaid, and private insurance reimbursement. Customers span three segments: end-user individuals with disabilities, clinicians and health systems (Northwell Health, Johns Hopkins, Mass General, Memorial Hermann, Veterans Health Administration, ALS Accel), and research institutions purchasing Axon-R for neuroscience and neurorehabilitation work. Distribution is multi-channel: Apple App Store for software, direct enterprise sales and Blackrock for research hardware, and (pending FDA clearance) clinical sales supported by insurance reimbursement.

Cognixion has assembled a strategic partner ecosystem that includes Amazon (Alexa Fund investment and Alexa integration), Apple (Vision Pro clinical co-development and accessibility API integration), Pupil Labs (eye-tracking integration), and Blackrock Neurotech (distribution), and holds granted US patents on BCI-for-AR and dynamic eye-tracking camera alignment. The company raised a $12 million seed round led by Prime Movers Lab in November 2021 with Northwell Health, Amazon Alexa Fund, and Volta Circle, followed by a February 2026 exempt offering of approximately $4.05 million, and is pre-revenue on its medical-device side pending FDA clearance of Cognixion ONE.

Short descriptiontext

Cognixion builds non-invasive brain-computer interface headsets and AAC software that restore communication for people with severe motor and speech impairments from ALS, stroke, and spinal cord injury, serving individuals, clinicians, and research institutions globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSanta Barbara, United States
HQ citystring
Santa Barbara
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
brain-computer interface, assistive communication technology, non-invasive neurotechnology, augmentative alternative communication, wearable EEG devices
Industry5 codes
PRIMARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYEDAKAIAB
AAC (Augmentative & Alternative Communication) Devices, Apps & Training
Education/Special Education & Learning Support Services/Assistive Technology (AT) Assessment, Devices & Training
SECONDARYEDAFAKAB
AAC (Augmentative & Alternative Communication) & Speech/Language Therapy Tech
Education/Education Technology (EdTech) & Digital Learning/Accessibility, Assistive Technology & Special Needs EdTech
SECONDARYHLACANAI
Behavioral Health & Neurocognitive Therapeutics (Digital)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYEDAFAKAC
Assistive Hearing & Communication Access (Captioning, Hearing Support, Transcription)
Education/Education Technology (EdTech) & Digital Learning/Accessibility, Assistive Technology & Special Needs EdTech
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing33451
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Brain-Computer Interface Devices
Social media profiles3 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Software Subscriptions (Speakprose)
TypeSubscription Recurring
Description

Monthly and annual subscription revenue from Speakprose and Speakprose Pro+ AAC communication apps distributed through Apple App Store. Pricing tiers: $9.99/month, $99.99/year, or $149.99 one-time unlimited purchase.

cognixion.com
2Hardware Sales (Cognixion ONE Axon-R)
TypeHardware Sales
Description

Sale of wearable BCI headset devices for research use. Axon-R is available for research institutions through direct sales and Blackrock Neurotech distribution partnership. Medical device (Cognixion ONE) pending FDA clearance for clinical commercial sale.

axon-r.cognixion.com
3Insurance Reimbursement (Future)
TypeManaged Services
Description

CMS accreditation obtained for durable medical equipment supplier status, enabling future Medicare, Medicaid, and private insurance reimbursement for Cognixion ONE upon FDA clearance.

cognixion.com
4Technology Licensing/Integration
TypeLicensing Royalties
Description

Licensing of BCI technology and SDK to research partners and integration partners (e.g., Pupil Labs eye-tracking integration, Blackrock Neurotech distribution)

mobihealthnews.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Others, Operations
Pricing details4 tiers
1Speakprose Monthly Subscription
ModelSubscriptionBilling cadenceMonthly
Notes

$9.99/month with free 30-day trial available. Includes core communication features with predictive keyboard.

cognixion.com
2Speakprose Annual Subscription
ModelSubscriptionBilling cadenceAnnual
Notes

$99.99/year (save $20 USD compared to monthly). Includes all monthly features.

cognixion.com
3Speakprose Unlimited (One-Time)
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

$149.99 one-time purchase for lifetime unlimited access.

cognixion.com
4Speakprose Pro+ Upgrade
ModelSubscriptionBilling cadenceMonthly
Notes

Upgrade within the free Speakprose app to Pro+ for eye and facial tracking control features. Pricing determined within app upgrade flow.

cognixion.com
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1Axon-R
Description

Non-invasive wearable brain-computer interface platform for research use, combining EEG technology with augmented reality and AI

cognixion.com
+4 more records
Core offering1 text field

Cognixion develops non-invasive brain-computer interface (BCI) hardware and AI-powered assistive communication software for individuals with severe motor and speech impairments. The company sells the Axon-R wearable EEG-based BCI research platform to research institutions, the Speakprose AAC (augmentative and alternative communication) application for iOS consumers, and is pursuing FDA clearance for the Cognixion ONE wearable speech-generating device combining wireless BCI with augmented reality for clinical and consumer use.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Communication speed up to 10x faster than traditional AAC solutions
+3 more records
Product and service3 records
1Cognixion ONE
CategoryAssistive Communication Hardware
Description

Wearable, wireless, non-invasive brain-computer interface headset with integrated augmented reality display designed for people with severe motor and speech impairments. Detects brain responses to visual stimuli and interprets user intent for letter/word selection to generate speech. Has received FDA Breakthrough Device Designation and CMS durable medical equipment supplier accreditation.

2Axon-R Research Platform
CategoryResearch BCI Platform
Description

Research-grade wearable EEG-based non-invasive BCI platform with augmented reality interface, designed for neuroscience, neurorehabilitation, and assistive technology research. Integrates multi-modal sensors and supports integration with Pupil Labs eye-tracking. Sold to universities, hospitals, and academic research programs through direct sales and Blackrock Neurotech distribution.

3Speakprose
CategoryAugmentative and Alternative Communication (AAC) Software
Description

Augmentative and Alternative Communication (AAC) application for iPhone and iPad using Apple TrueDepth camera for eye-tracking and facial-recognition control. Includes predictive keyboard, adaptive AI language support, and Amazon Alexa integration for hands-free smart home control and communication. Available as Speakprose (with optional Speakprose Pro+ in-app upgrade for enhanced eye and facial tracking).

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-10-02
Description

Clinical study integration of Cognixion's EEG-based BCI with Apple Vision Pro spatial computing platform. Study leverages Apple accessibility features (Eye Tracking, Dwell Control, Switch Control) combined with Cognixion's Nucleus bio-sensing hub and custom EEG headband. Apple's hardware and accessibility APIs serve as platform for Cognixion's clinical research.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-06-04
Description

Strategic partnership to combine Cognixion's BCI/EEG/AI/AR technologies with Pupil Labs' advanced eye-tracking solutions. Integration of Pupil Labs' NeonNet eye-tracking software with Axon-R SDK enables seamless cross-platform data collection measuring both visual attention and neural signals. Technical teams began integration with initial releases expected within six months.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-05-14
Description

Distribution partnership where Blackrock Neurotech (leading implantable BCI developer) offers Cognixion's Axon-R wearable BCI platform to research institutions through its distribution network. Non-exclusive distribution agreement enables universities and hospitals to access research-grade non-invasive BCI tools alongside Blackrock's implantable solutions.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Partial funder of clinical trial for Cognixion Axon-R in ALS patients. ALS Accel is a subsidiary of the ALS Association providing funding and support for ALS research and technology development.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-06-30
Description

Clinical collaboration for BCI applications research with prestigious research institution

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-06-30
Description

Clinical research partnership for validation of BCI technology in hospital setting

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-06-30
Description

Healthcare system partnership for clinical applications of BCI technology

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-06-30
Description

Federal healthcare system partnership for BCI research and veteran applications

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-11-16
Description

Co-investor in seed funding and clinical development partner. Northwell Health is New York's largest healthcare provider. Dr. Souhel Najjar from Northwell expressed clinical collaboration to assess efficacy of Cognixion technology. Northwell Holdings & Ventures supporting expansion into healthcare provider markets.

10Tom Gruber (Creator of Siri)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-12-09
Description

World's first and best conversational AI expert teamed up with Cognixion bringing expertise in natural language AI to enhance Cognixion's adaptive AI language systems for communication

cognixion.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

EEG-based BCI company building consumer and productivity neurotechnology (e.g., Enten headphones). Comparable core technology (EEG + AI), but a different end market (consumer wellness/productivity vs. assistive communication) and therefore only partial overlap with Cognixion.

TypeDirect peer
Description

Direct competitor building a high-bandwidth implantable BCI with an FDA-cleared human trial program. Targets similar communication and mobility use cases; its surgical approach represents the primary alternative pathway to the same patient populations Cognixion addresses.

TypeEmerging player
Description

Open-source EEG hardware and software platform for research and hobbyist BCI applications. Comparable technology stack and developer ecosystem, but positioned at lower price points for research and education rather than clinical or assistive deployment.

TypeEmerging player
Description

Emerging competitor in implantable BCI focused on high-resolution cortical interfaces. Targets overlapping clinical use cases in paralysis and communication, representing another well-funded implant alternative to Cognixion's non-invasive wearable.

TypeBroad incumbent
Description

Market-leading AAC and eye-tracking assistive technology vendor. Comparable because it serves the same severe speech-impairment population with eye-gaze-based communication devices, and is the primary incumbent alternative to Cognixion's products (Director of PM Lucas Steuber is a former Tobii Dynavox executive).

TypeBroad incumbent
Description

Established implantable BCI incumbent and research-platform leader; also Cognixion's distribution partner for Axon-R. Comparable because it sells BCI hardware (research-grade and clinical) to the same institutions Cognixion targets, and competes in the broader assistive BCI category with a different modality.

TypeEmerging player
Description

Consumer and research EEG headset maker with an established developer ecosystem. Comparable EEG-based hardware, but focused on wellness, gaming, and research rather than severe-disability communication.

TypeDirect peer
Description

Direct competitor developing a minimally invasive (endovascular) BCI aimed at restoring communication and digital control for paralyzed patients. Comparable target population (severe motor/speech impairment) and overlapping FDA pathway, but a fundamentally different (surgical) delivery mechanism that contrasts with Cognixion's non-invasive approach.

TypeBroad incumbent
Description

Established iOS AAC app developer (Proloquo, Proloquo4Text) serving the same augmentative communication market as Cognixion's Speakprose. Comparable product category and end-user population, though without BCI or AR hardware integration.

TypeOthers
Description

Eye-tracking hardware and software vendor, also a strategic integration partner with Cognixion. Adjacent ecosystem participant: supplies the eye-tracking layer that Cognixion's Nucleus and Axon-R products combine with EEG for multi-modal assistive communication.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat7 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration5 records

Each record includes

Title, Type, Description, Source

AI capability8 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cognixion

Brain-Computer Interface Devicescognixion.com

Cognixion builds non-invasive brain-computer interface headsets and AAC software that restore communication for people with severe motor and speech impairments from ALS, stroke, and spinal cord injury, serving individuals, clinicians, and research institutions globally.

What Cognixion does

Cognixion is a Santa Barbara-headquartered neurotechnology company founded in 2014 by Andreas Forsland that develops non-invasive brain-computer interface (BCI) products to restore communication and environmental control for individuals with severe motor and speech impairments, including ALS, spinal cord injury, stroke, cerebral palsy, and locked-in syndrome. Its core platform combines EEG-based neural signal acquisition, augmented reality (AR) display, eye tracking, head-pose sensing, and adaptive AI language models into a wearable headset (Cognixion ONE / Axon-R) that lets users generate text and speech through thought, gaze, or facial expressions. The company also sells Speakprose and Speakprose Pro+, consumer AAC apps on the Apple App Store that leverage the Apple TrueDepth camera for eye and facial tracking, and a Nucleus bio-sensing hub that integrates with Apple Vision Pro's accessibility APIs in an ongoing clinical study.

The business model combines consumer software subscriptions (Speakprose at $9.99/month, $99.99/year, or $149.99 one-time), research-hardware sales of the Axon-R platform through direct sales and a distribution partnership with Blackrock Neurotech, and a future medical-device revenue stream gated on FDA clearance of Cognixion ONE, after which CMS accreditation as a durable medical equipment supplier is expected to enable Medicare, Medicaid, and private insurance reimbursement. Customers span three segments: end-user individuals with disabilities, clinicians and health systems (Northwell Health, Johns Hopkins, Mass General, Memorial Hermann, Veterans Health Administration, ALS Accel), and research institutions purchasing Axon-R for neuroscience and neurorehabilitation work. Distribution is multi-channel: Apple App Store for software, direct enterprise sales and Blackrock for research hardware, and (pending FDA clearance) clinical sales supported by insurance reimbursement.

Cognixion has assembled a strategic partner ecosystem that includes Amazon (Alexa Fund investment and Alexa integration), Apple (Vision Pro clinical co-development and accessibility API integration), Pupil Labs (eye-tracking integration), and Blackrock Neurotech (distribution), and holds granted US patents on BCI-for-AR and dynamic eye-tracking camera alignment. The company raised a $12 million seed round led by Prime Movers Lab in November 2021 with Northwell Health, Amazon Alexa Fund, and Volta Circle, followed by a February 2026 exempt offering of approximately $4.05 million, and is pre-revenue on its medical-device side pending FDA clearance of Cognixion ONE.

Cognixion firmographics

Firmographics
Name
Cognixion
Legal name
COGNIXION, INC.
Website
https://cognixion.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
Cognixion builds non-invasive brain-computer interface headsets and AAC software that restore communication for people with severe motor and speech impairments from ALS, stroke, and spinal cord injury, serving individuals, clinicians, and research institutions globally.
Ownership category
akta.pro rank

Cognixion industry classification

Industry
Product category
Brain-Computer Interface Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYEDAKAIAB
AAC (Augmentative & Alternative Communication) Devices, Apps & Training
Education/Special Education & Learning Support Services/Assistive Technology (AT) Assessment, Devices & Training
SECONDARYEDAFAKAB
AAC (Augmentative & Alternative Communication) & Speech/Language Therapy Tech
Education/Education Technology (EdTech) & Digital Learning/Accessibility, Assistive Technology & Special Needs EdTech
SECONDARYHLACANAI
Behavioral Health & Neurocognitive Therapeutics (Digital)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYEDAFAKAC
Assistive Hearing & Communication Access (Captioning, Hearing Support, Transcription)
Education/Education Technology (EdTech) & Digital Learning/Accessibility, Assistive Technology & Special Needs EdTech

Keywords

  • Brain-computer interface
  • Assistive communication technology
  • Non-invasive neurotechnology
  • Augmentative alternative communication
  • Wearable EEG devices

Where Cognixion is headquartered

Location

Headquarters

HQ city
Santa Barbara
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Cognixion business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Others, Operations

Revenue model

  1. Software Subscriptions (Speakprose): Monthly and annual subscription revenue from Speakprose and Speakprose Pro+ AAC communication apps distributed through Apple App Store. Pricing tiers: $9.99/month, $99.99/year, or $149.99 one-time unlimited purchase.
  2. Hardware Sales (Cognixion ONE Axon-R): Sale of wearable BCI headset devices for research use. Axon-R is available for research institutions through direct sales and Blackrock Neurotech distribution partnership. Medical device (Cognixion ONE) pending FDA clearance for clinical commercial sale.
  3. Insurance Reimbursement (Future): CMS accreditation obtained for durable medical equipment supplier status, enabling future Medicare, Medicaid, and private insurance reimbursement for Cognixion ONE upon FDA clearance.
  4. Technology Licensing/Integration: Licensing of BCI technology and SDK to research partners and integration partners (e.g., Pupil Labs eye-tracking integration, Blackrock Neurotech distribution)

Pricing tiers

ModelBillingPrice
SubscriptionMonthlySpeakprose Monthly Subscription
SubscriptionAnnualSpeakprose Annual Subscription
One time/ perpetual licensePay-as-you-goSpeakprose Unlimited (One-Time)
SubscriptionMonthlySpeakprose Pro+ Upgrade

Go-to-market motion3 records

Distribution channels5 records

Marketing channels8 records

Cognixion product offering

Product offering

Core offering

Cognixion develops non-invasive brain-computer interface (BCI) hardware and AI-powered assistive communication software for individuals with severe motor and speech impairments. The company sells the Axon-R wearable EEG-based BCI research platform to research institutions, the Speakprose AAC (augmentative and alternative communication) application for iOS consumers, and is pursuing FDA clearance for the Cognixion ONE wearable speech-generating device combining wireless BCI with augmented reality for clinical and consumer use.

Differentiator

Problem solved

Functional benefit

Brands

  • Axon-R: Non-invasive wearable brain-computer interface platform for research use, combining EEG technology with augmented reality and AI
  • Cognixion ONE
  • Speakprose
  • Speakprose Pro+
  • Nucleus

Products and services

  • Cognixion ONE Wearable, wireless, non-invasive brain-computer interface headset with integrated augmented reality display designed for people with severe motor and speech impairments. Detects brain responses to visual stimuli and interprets user intent for letter/word selection to generate speech. Has received FDA Breakthrough Device Designation and CMS durable medical equipment supplier accreditation.
  • Axon-R Research Platform Research-grade wearable EEG-based non-invasive BCI platform with augmented reality interface, designed for neuroscience, neurorehabilitation, and assistive technology research. Integrates multi-modal sensors and supports integration with Pupil Labs eye-tracking. Sold to universities, hospitals, and academic research programs through direct sales and Blackrock Neurotech distribution.
  • Speakprose Augmentative and Alternative Communication (AAC) application for iPhone and iPad using Apple TrueDepth camera for eye-tracking and facial-recognition control. Includes predictive keyboard, adaptive AI language support, and Amazon Alexa integration for hands-free smart home control and communication. Available as Speakprose (with optional Speakprose Pro+ in-app upgrade for enhanced eye and facial tracking).

Quantifiable outcome

  • Communication speed up to 10x faster than traditional AAC solutions
  • +3 more outcomes

Companies that use Cognixion

Customer profile

Named customers7 records

Segments4 records

Ideal customer profiles4 records

Cognixion technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration5 records

AI capability8 records

Feature5 records

Cognixion partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core and minor.

  • ApplecoreTechnology or Integration · 2 October 2025Clinical study integration of Cognixion's EEG-based BCI with Apple Vision Pro spatial computing platform. Study leverages Apple accessibility features (Eye Tracking, Dwell Control, Switch Control) combined with Cognixion's Nucleus bio-sensing hub and custom EEG headband. Apple's hardware and accessibility APIs serve as platform for Cognixion's clinical research.
  • Pupil LabscoreTechnology or Integration · 4 June 2025Strategic partnership to combine Cognixion's BCI/EEG/AI/AR technologies with Pupil Labs' advanced eye-tracking solutions. Integration of Pupil Labs' NeonNet eye-tracking software with Axon-R SDK enables seamless cross-platform data collection measuring both visual attention and neural signals. Technical teams began integration with initial releases expected within six months.
  • Blackrock NeurotechcoreChannel Partner/ Reseller/ Distributor · 14 May 2025Distribution partnership where Blackrock Neurotech (leading implantable BCI developer) offers Cognixion's Axon-R wearable BCI platform to research institutions through its distribution network. Non-exclusive distribution agreement enables universities and hospitals to access research-grade non-invasive BCI tools alongside Blackrock's implantable solutions.
  • ALS Accel (ALS Association subsidiary)coreStrategic or Co-development Partner · 1 January 2025Partial funder of clinical trial for Cognixion Axon-R in ALS patients. ALS Accel is a subsidiary of the ALS Association providing funding and support for ALS research and technology development.
  • Johns HopkinscoreStrategic or Co-development Partner · 30 June 2024Clinical collaboration for BCI applications research with prestigious research institution
  • Mass General HospitalcoreStrategic or Co-development Partner · 30 June 2024Clinical research partnership for validation of BCI technology in hospital setting
  • Memorial Hermann Health SystemminorStrategic or Co-development Partner · 30 June 2024Healthcare system partnership for clinical applications of BCI technology
  • Veterans Health AdministrationminorStrategic or Co-development Partner · 30 June 2024Federal healthcare system partnership for BCI research and veteran applications
  • Northwell HealthcoreStrategic or Co-development Partner · 16 November 2021Co-investor in seed funding and clinical development partner. Northwell Health is New York's largest healthcare provider. Dr. Souhel Najjar from Northwell expressed clinical collaboration to assess efficacy of Cognixion technology. Northwell Holdings & Ventures supporting expansion into healthcare provider markets.
  • Tom Gruber (Creator of Siri)coreStrategic or Co-development Partner · 9 December 2019World's first and best conversational AI expert teamed up with Cognixion bringing expertise in natural language AI to enhance Cognixion's adaptive AI language systems for communication

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Cognixion competitors and assessment

Company assessment

Emerging players

  • Neurable: EEG-based BCI company building consumer and productivity neurotechnology (e.g., Enten headphones). Comparable core technology (EEG + AI), but a different end market (consumer wellness/productivity vs. assistive communication) and therefore only partial overlap with Cognixion.
  • OpenBCI: Open-source EEG hardware and software platform for research and hobbyist BCI applications. Comparable technology stack and developer ecosystem, but positioned at lower price points for research and education rather than clinical or assistive deployment.
  • Precision Neuroscience: Emerging competitor in implantable BCI focused on high-resolution cortical interfaces. Targets overlapping clinical use cases in paralysis and communication, representing another well-funded implant alternative to Cognixion's non-invasive wearable.
  • Emotiv: Consumer and research EEG headset maker with an established developer ecosystem. Comparable EEG-based hardware, but focused on wellness, gaming, and research rather than severe-disability communication.

Direct peers

  • Neuralink: Direct competitor building a high-bandwidth implantable BCI with an FDA-cleared human trial program. Targets similar communication and mobility use cases; its surgical approach represents the primary alternative pathway to the same patient populations Cognixion addresses.
  • Synchron: Direct competitor developing a minimally invasive (endovascular) BCI aimed at restoring communication and digital control for paralyzed patients. Comparable target population (severe motor/speech impairment) and overlapping FDA pathway, but a fundamentally different (surgical) delivery mechanism that contrasts with Cognixion's non-invasive approach.

Broad incumbents

  • Tobii Dynavox: Market-leading AAC and eye-tracking assistive technology vendor. Comparable because it serves the same severe speech-impairment population with eye-gaze-based communication devices, and is the primary incumbent alternative to Cognixion's products (Director of PM Lucas Steuber is a former Tobii Dynavox executive).
  • Blackrock Neurotech: Established implantable BCI incumbent and research-platform leader; also Cognixion's distribution partner for Axon-R. Comparable because it sells BCI hardware (research-grade and clinical) to the same institutions Cognixion targets, and competes in the broader assistive BCI category with a different modality.
  • AssistiveWare: Established iOS AAC app developer (Proloquo, Proloquo4Text) serving the same augmentative communication market as Cognixion's Speakprose. Comparable product category and end-user population, though without BCI or AR hardware integration.

Others

  • Pupil Labs: Eye-tracking hardware and software vendor, also a strategic integration partner with Cognixion. Adjacent ecosystem participant: supplies the eye-tracking layer that Cognixion's Nucleus and Axon-R products combine with EEG for multi-modal assistive communication.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

Cognixion social profiles

Digital presence

Cognixion financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cognixion leadership team

Management profile

Number of profiles

Profiles5 records

Cognixion funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cognixion M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cognixion

What does Cognixion do?

Cognixion develops non-invasive brain-computer interface (BCI) hardware and AI-powered assistive communication software for individuals with severe motor and speech impairments. The company sells the Axon-R wearable EEG-based BCI research platform to research institutions, the Speakprose AAC (augmentative and alternative communication) application for iOS consumers, and is pursuing FDA clearance for the Cognixion ONE wearable speech-generating device combining wireless BCI with augmented reality for clinical and consumer use.

Is Cognixion a public or private company?

Cognixion is a private company. It is classified as venture growth investor backed and is currently operating.

When was Cognixion founded?

Cognixion was founded in 2014. It employs 11 to 50 people.

Where is Cognixion based?

Cognixion is headquartered in Santa Barbara, United States, in the North America region.

How does Cognixion make money?

Four revenue lines are on record. Software Subscriptions (Speakprose) is the primary driver. The others are hardware Sales (Cognixion ONE Axon-R), insurance Reimbursement (Future) and technology Licensing/Integration.

Who are Cognixion's main competitors?

Emerging players on record are Neurable, OpenBCI, Precision Neuroscience and Emotiv. Direct peers are Neuralink and Synchron. Broad incumbents are Tobii Dynavox, Blackrock Neurotech and AssistiveWare. Pupil Labs is listed as an others.

Does Cognixion have an API?

No public API is recorded for Cognixion.

What industry is Cognixion in?

Cognixion's product category is Brain-Computer Interface Devices. Its primary akta.pro industry code is HLAHACAE, Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables), with a secondary code of EDAKAIAB, AAC (Augmentative & Alternative Communication) Devices, Apps & Training. Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireGlobal AI Leaders to Headline LEAP 2026 as Riyadh Marks the Year of AILEAP 2026 will be held in Riyadh, Saudi Arabia, with AMD and HUMAIN leaders headlining, as the Kingdom marks 2026 as the Year of AI. The event will feature 93% live demonstrations, up from 62% in 2025, and over three-quarters of Saudi organizations expect AI to deliver ROI within 12 months.SecSEC FORM DCognixion Corp filed a Form D notice with the SEC on February 2, 2026, reporting an exempt offering of debt securities totaling $4,050,000, with the first sale occurring on January 30, 2026. The offering was conducted under Rule 506(b) and Rule 506(c) exemptions and involved four investors. The filing was signed by CEO Andreas Forsland, and the company is headquartered in Santa Barbara, California.CognixionCognixion Blog — Cognixion®Cognixion is conducting a clinical feasibility study integrating its non-invasive Axon-R brain-computer interface with Apple Vision Pro to enable communication for patients with ALS and other neurological conditions. The company has also announced strategic partnerships with Pupil Labs to combine eye-tracking technology with neural interfaces, and Blackrock Neurotech to distribute the Axon-R platform to research institutions.CognixionInside Cognixion’s Non-Invasive BCI Study: Advancing Communication Through Thought — Cognixion®Cognixion's ongoing feasibility study of its Axon-R non-invasive brain-computer interface and Nucleus bio-sensing hub was highlighted in a new Clinical Leader feature. The research explores integrating brain signals, eye tracking, and AI with Apple Vision Pro to support communication for patients with ALS and similar conditions. Cognixion CTO Chris Ullrich discussed the system's development based on patient feedback and regulatory considerations.CognixionCognixion®Cognixion is promoting its Axon-R platform, a noninvasive brain-computer interface that integrates neuroscience and AI to assist individuals with complex disabilities. The company describes the technology as enabling control over communication, mobility, and smart home devices through mind and eye inputs while partnering with health systems for clinical applications.9to5MacApple @ Work: How Apple Vision Pro is helping redefine accessibility through non-invasive brain-computer interfacesApple Vision Pro is being used in a clinical study by Cognixion to explore how it can help people with neurological conditions communicate using brain signals, eye tracking, and AI. The study, which runs until April 2026, aims to improve accessibility technology without requiring surgery, leveraging Apple’s hardware and software features.CognixionRedefining Accessibility: How Apple Vision Pro and Cognixion Are Advancing Non-Invasive Brain-Computer Interfaces — Cognixion®Cognixion is conducting a clinical study utilizing Apple Vision Pro to advance non-invasive brain-computer interfaces for individuals with neurological conditions. The research combines Cognixion’s EEG-based Nucleus™ technology with Apple’s accessibility features, such as eye tracking and AI, to enable communication through thought and gaze without surgical implants. This collaboration aims to restore independence for patients by leveraging spatial computing to decode brain signals within a user-friendly interface.9to5MacApple @ Work Podcast: Inside Cognixion’s study using Vision Pro to give voice through brain signals and AICognixion is conducting a clinical study using Apple Vision Pro to help people with conditions like ALS, spinal cord injuries, and stroke-related impairments communicate through a combination of brain signals, eye tracking, and AI. Chris Ullrich from Cognixion appeared as a guest on the Apple @ Work podcast to discuss the study. The article is a podcast episode description with minimal substantive detail beyond the basic announcement.CognixionCognixion and Pupil Labs Announce Strategic Partnership to Combine<br/>Eye-Tracking with BCI — Cognixion®Cognixion and Pupil Labs announced a strategic partnership to integrate Cognixion's brain-computer interface technology with Pupil Labs' eye-tracking solutions. The collaboration aims to provide clinical researchers with unified tools that simultaneously measure visual attention and neural activity, particularly for applications in neuroscience and assistive technologies. Initial releases of the integrated software are expected within six months.CognixionClinical Trial News: Cognixion + Apple Vision Pro — Cognixion®Cognixion has launched a clinical study integrating its noninvasive EEG-based brain-computer interface technology with Apple Vision Pro to assist individuals with severe speech and mobility impairments. The trial aims to enable hands-free communication and interaction through thought, gaze, or head movement for patients with conditions such as ALS, spinal cord injury, stroke, and traumatic brain injury.